Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
Parkinson's disease
type 2 diabetes
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
12
01
2021
received:
11
11
2020
accepted:
01
02
2021
pubmed:
9
3
2021
medline:
24
6
2021
entrez:
8
3
2021
Statut:
ppublish
Résumé
Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting. The objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data. A systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies. In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression. Using meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Type 2 diabetes (T2DM) and Parkinson's disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting.
OBJECTIVE
The objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data.
METHODS
A systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies.
RESULTS
In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression.
CONCLUSIONS
Using meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 33682937
doi: 10.1002/mds.28551
pmc: PMC9017318
mid: NIHMS1794654
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1420-1429Subventions
Organisme : Michael J. Fox Foundation
Organisme : Young Investigator Award by Parkinson Canada
Organisme : Intramural NIH HHS
ID : Z99 AG999999
Pays : United States
Organisme : Canada First Research Excellence Fund (CFREF)
Organisme : The Barts Charity
Organisme : Intramural Research Program of the NIH, National Institute on Aging
Organisme : Canadian Consortium on Neurodegeneration in Aging (CCNA)
Organisme : Fonds de recherche du Québec-Santé (FRQS)
Informations de copyright
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
Diabetes Care. 2011 Dec;34(12):2614-23
pubmed: 22110170
Diabetes Care. 2011 Apr;34(4):910-5
pubmed: 21378214
Diabetes Metab. 2021 May;47(3):101195
pubmed: 33039669
Stat Med. 2000 Nov 30;19(22):3127-31
pubmed: 11113947
Arch Neurol. 2007 Apr;64(4):570-5
pubmed: 17420320
PLoS Med. 2017 Jun 13;14(6):e1002314
pubmed: 28609445
Medicine (Baltimore). 2016 May;95(18):e3549
pubmed: 27149468
Parkinsons Dis. 2019 Nov 23;2019:4951379
pubmed: 31871617
Acta Neurol Scand. 1994 Mar;89(3):164-70
pubmed: 8030397
Diabetes Care. 2012 May;35(5):1047-9
pubmed: 22432112
Front Neurosci. 2020 Sep 23;14:547175
pubmed: 33100956
Neurology. 2009 Nov 3;73(18):1462-8
pubmed: 19776374
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Int J Epidemiol. 2019 Jun 1;48(3):728-742
pubmed: 30561657
Neurology. 2018 May 8;90(19):e1654-e1662
pubmed: 29626177
Diabetes Care. 2011 May;34(5):1102-8
pubmed: 21411503
Am J Epidemiol. 1994 Jun 15;139(12):1129-38
pubmed: 8209872
Neurology. 2018 Jul 10;91(2):e139-e142
pubmed: 29898968
Elife. 2018 May 30;7:
pubmed: 29846171
Parkinsonism Relat Disord. 2013 Jan;19(1):53-5
pubmed: 22841686
Acta Neurol Scand. 2017 Dec;136(6):732-736
pubmed: 28653373
Epidemiology. 2017 Jan;28(1):30-42
pubmed: 27749700
Lancet Neurol. 2019 Dec;18(12):1091-1102
pubmed: 31701892
J Neurochem. 2005 Apr;93(1):105-17
pubmed: 15773910
Mov Disord. 2019 Dec;34(12):1839-1850
pubmed: 31505070
Parkinsonism Relat Disord. 2006 Apr;12(3):185-9
pubmed: 16364673
J Neurol Sci. 2017 Jun 15;377:122-126
pubmed: 28477681
Mov Disord. 2016 Oct;31(10):1518-1526
pubmed: 27324570
Brain. 2020 Oct 1;143(10):3067-3076
pubmed: 33011770
Neurology. 2007 Oct 23;69(17):1688-95
pubmed: 17761552
Can J Neurol Sci. 2001 May;28(2):144-7
pubmed: 11383940
Mov Disord. 2012 Jul;27(8):974-9
pubmed: 22674432
Int J Epidemiol. 2011 Jun;40(3):755-64
pubmed: 21414999
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
Stat Med. 2008 Apr 15;27(8):1133-63
pubmed: 17886233
Diabetes Care. 2008 Oct;31(10):2003-5
pubmed: 18599528
JAMA Neurol. 2020 Jan 1;77(1):7-8
pubmed: 31609383
Nat Rev Endocrinol. 2011 Sep 13;8(2):92-103
pubmed: 21912398
Neurology. 2012 May 8;78(19):1507-11
pubmed: 22539572
Int J Epidemiol. 2014 Jun;43(3):922-9
pubmed: 24608958
Nat Genet. 2020 Jul;52(7):680-691
pubmed: 32541925
Postgrad Med J. 2005 Aug;81(958):486-90
pubmed: 16085737
Int J Epidemiol. 2007 Feb;36(1):244-6
pubmed: 17169941
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Prog Neurobiol. 2016 Oct - Nov;145-146:98-120
pubmed: 27713036
Parkinsonism Relat Disord. 2009 Nov;15(9):660-4
pubmed: 19356970
Mov Disord. 2011 Oct;26(12):2253-9
pubmed: 21739472
Lancet. 2017 Oct 7;390(10103):1664-1675
pubmed: 28781108
PLoS One. 2014 Jan 21;9(1):e85781
pubmed: 24465703
J Parkinsons Dis. 2020;10(1):31-45
pubmed: 31868680
Ann Neurol. 2012 Dec;72(6):893-901
pubmed: 23071076
PLoS Genet. 2017 Nov 17;13(11):e1007081
pubmed: 29149188
J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1046-1054
pubmed: 32934108
Diabetes Care. 2007 Apr;30(4):842-7
pubmed: 17251276
Mov Disord. 2006 Apr;21(4):446-55
pubmed: 16161155
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12473-12477
pubmed: 27791129
Medicine (Baltimore). 2017 Jan;96(3):e5921
pubmed: 28099356
Diabetes Metab Syndr Obes. 2017 Aug 14;10:345-361
pubmed: 28860833
J Neurol Sci. 2010 Jun 15;293(1-2):82-6
pubmed: 20347450
Hum Mol Genet. 2019 Jan 1;28(1):166-174
pubmed: 30239722
Am J Epidemiol. 1972 Oct;96(4):242-54
pubmed: 5074681
J Parkinsons Dis. 2020;10(3):775-789
pubmed: 32333549
Front Neurosci. 2018 Feb 20;12:73
pubmed: 29515352